PF-07832837 / Pfizer - LARVOL DELTA

C4991001: FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients (clinicaltrials.gov) - P1 | N=111 | Recruiting | Sponsor: Pfizer | Trial completion date: Oct 2027 ➔ Jun 2027 | Trial primary completion date: Oct 2027 ➔ Jun 2027

Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

C4991001: FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients (clinicaltrials.gov) - P1 | N=111 | Recruiting | Sponsor: Pfizer | Trial primary completion date: Apr 2027 ➔ Oct 2027 | Trial completion date: Apr 2027 ➔ Oct 2027

Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

C4991001: FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients (clinicaltrials.gov) - P1 | N=111 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

C4991001: FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients (clinicaltrials.gov) - P1 | N=111 | Not yet recruiting | Sponsor: Pfizer | Trial completion date: Sep 2026 ➔ May 2027 | Trial primary completion date: Sep 2026 ➔ May 2027

Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients (clinicaltrials.gov) - P1 | N=143 | Not yet recruiting | Sponsor: Pfizer

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology